![]() ![]() ![]() Food and Drug Administration requires additional drug-interaction safety studies to ensure that any therapeutic candidate is safe in people with CUD who may use cocaine while in treatment. ![]() Although a prior clinical study demonstrated that the compound is well tolerated in humans, cocaine has inherent proconvulsant and adverse cardiovascular effects, so the U.S. The first is to conduct interaction/toxicology studies of OMS527 in rats and non-human primates. Following peer review including leaders in the field from academia and industry, grant funding was awarded on April 7, 2023. To advance NIDA’s urgent medication development priorities for substance use disorders, Omeros submitted a grant application in 2022 to assess the potential of PDE7 inhibition as a treatment for CUD. The grant is expected to provide $6.69 million over three years and is intended to support both preclinical cocaine interaction studies and a clinical study evaluating the safety and efficacy of OMS527 in patients with CUD. Omeros Corporation (Nasdaq: OMER) today announced that it has been awarded a grant from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, to develop Omeros’ lead orally administered compound from its proprietary phosphodiesterase 7 (PDE7) program OMS527 for the treatment of cocaine use disorder (CUD). Its product pipeline is focused on complement-associated thrombotic microangiopathies complement-mediated glomerulonephropathies Huntington's disease and cognitive impairment and addictive and compulsive disorders.Ĭlick Here to get the full Stock Report for Omeros Corporation stock.– Directs Company to Advance its Lead Proprietary PDE7 Inhibitor to Treat Cocaine Use Disorder – for use during cataract surgery and intraocular lens replacement. Food and Drug Administration and launched in the U.S. The company owns Omidria (phenylephrine and ketorolac injection), approved by the U.S. Its goal is to research, develop, and commercialize small-molecule and protein therapeutics targeting inflammation, coagulopathies, and disorders of the central nervous system. Omeros Corp is a United States-based biopharmaceutical company. Volume today is 456,461 compared to average volume of 591,662. The stock has traded between $6.89 and $7.57 so far today. Omeros Corporation (OMER) stock is trading at $7.46 as of 1:19 PM on Friday, Jun 2, a rise of $0.18, or 2.47% from the previous closing price of $7.28. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend.Īvailable options can also represent current sentiments for a given stock. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. Recent trends are a good indicator of current market sentiments. There is no information about the health of profitability of the underlying company in our sentiment score.Īs a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Sentiment is a very short-term indicator that is entirely technical. See Full OMER Report What is Stock Sentiment? ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |